We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Goldsite Diagnostics

Goldsite Diagnostics Inc. focuses on the development, manufacturing and sales of clinical laboratory devices and in-... read more Featured Products: More products

Download Mobile App




Portable POCT Immunofluorescence Analyzer Makes Testing Smarter, Faster and More Efficient

By LabMedica International staff writers
Posted on 12 May 2023

With existing POCT dry fluorescence methods it can be difficult to meet the accurate and sensitive detection requirements for clinical samples. More...

The new time-resolved fluorescence immunoassay (TRFIA) technology uses time-resolved techniques to measure fluorescence, combines long decay lifetime markers with time-resolved fluorescence, effectively eliminating non-specific fluorescence interference and greatly improving analytical sensitivity. Now, a new time-resolved immunofluorescence analyzer uses TRFIA technology to quantitatively measure the concentration of analytes in blood or other samples at the POC.

The FIA Go from Goldsite Diagnostics Inc. (Shenzhen, China) is a compact fluorescent immunoassay analyzer designed for POCT settings. The rapid, quantitative instrument is based on TRFIA technology for high precision and low interference. The high-performance portable analyzer with a wide-ranging parameter menu provides professionals with high-quality medical information and user-friendly handling.

Featuring easy operation and an Android operating system, the FIA Go analyzer supports multiple tests, including Vitamin D, Ferritin, Folic acid, hormones, thyroid panels, etc. With its one-step operation, the FIA Go analyzer provides fast and accurate results in minutes at the POC, making it suitable for delivering timely primary care at the physician's office. Other flexible application scenarios include clinical laboratories, clinical departments, emergency outpatient clinics, and ambulances.

Related Links:
Goldsite Diagnostics 


New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Urine Analyzer
respons® UDS100
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The integrated polygenic risk score combines information from multiple genetic variants into a single test that provides a result for each of eight cardiovascular conditions (photo credit: Adobe Stock)

Genomic Risk Score Identifies Inherited Risk for Multiple Cardiovascular Conditions

Cardiovascular disease is the leading cause of death worldwide, yet many at‑risk individuals are overlooked by traditional calculators. Tools that weigh age, sex, blood pressure, and cholesterol can miss... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.